A Phase 1b/2 Placebo Controlled, Double Blinded Study on the Efficacy and Safety of BXQ-350 in Combination With mFOLFOX7 and Bevacizumab in Newly Diagnosed Metastatic Colorectal Carcinoma

The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7.
All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine the Stage 2 dose. Stage 2 will be blinded; participants will receive BXQ-350 at the established Stage 1 dose or placebo.

开始日期2023-01-09

申办/合作机构

Bexion Pharmaceuticals, Inc.

[+2]

NCT05291286

/ Completed早期临床1期

A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy

This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized, placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.

开始日期2022-10-17

申办/合作机构

Bexion Pharmaceuticals, Inc.

[+1]

NCT04771897

/ Terminated临床1期

A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)

This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy. The study is divided into two parts: Part 1 will enroll patients at increasing dose levels of BXQ-350 in order to determine the MTD. Part 2 will enroll patients requiring a biopsy in order to assess BXQ-350 concentrations in the biopsied tumor.

开始日期2021-05-24

申办/合作机构

Bexion Pharmaceuticals, Inc.

[+1]

100 项与 BXQ-350 相关的临床结果

登录后查看更多信息

100 项与 BXQ-350 相关的转化医学

登录后查看更多信息

100 项与 BXQ-350 相关的专利（医药）

登录后查看更多信息

项与 BXQ-350 相关的文献（医药）

2024-11-15·CLINICAL CANCER RESEARCH

A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas

Article

作者: Curry, Richard ; Ogretmen, Besim ; Noonan, Anne M. ; Tapolsky, Gilles ; Cruze, Charlie ; Villano, John L. ; Wesolowski, Robert ; Yilmaz, Emrullah ; Wise-Draper, Trisha M. ; Rixe, Olivier ; Takigiku, Ray ; Puduvalli, Vinay K.

Abstract:

Purpose::

BXQ-350, a nanovesicle formulation of saposin C, is an allosteric sphingolipid metabolism regulator that increases proapoptotic ceramide and decreases oncogenic sphingosine-1-phosphate levels. We conducted a first-in-human phase I study of BXQ-350.

Patients and Methods::

Adults (≥18 years old) with advanced/recurrent, treatment-refractory solid tumors or high-grade gliomas received BXQ-350 intravenously in five dose cohorts (0.7–2.4 mg/kg) in a 3+3 dose escalation and expansion design. The primary endpoints during dose escalation were dose-limiting toxicities and maximum tolerated dose; the primary objective in expansion parts was assessment of antitumor activity (RECIST v1.1/Response Assessment in Neuro-Oncology criteria).

Results::

Eighty-six patients were enrolled. Dose-limiting toxicities were not observed during dose escalation (n = 18), and a maximum tolerated dose was not identified. An additional 68 patients received the 2.4 mg/kg dose. Nine patients (10%) discontinued due to adverse events. The most common treatment-related adverse events were nausea (24%) and fatigue (23%). Eight patients had a progression-free survival of ≥6 months. Two of these achieved a partial response, and six had stable disease, among whom three had a reduction in ≥1 target lesion. Of those with progression-free survival of ≥6 months, seven remained on study for >12 months, five for >24 months, and after 7 years, two remained on study without disease progression.

Conclusions::

BXQ-350 was well-tolerated as monotherapy at doses up to 2.4 mg/kg. It provided some lasting clinical benefit in patients with recurrent solid malignancies across several tumor types, consistent with a decreased systemic sphingosine-1-phosphate/ceramide metabolic rheostat. BXQ-350 warrants further clinical investigation alone and combined with standard of care for advanced solid tumors.

2022-12-01·Heliyon

An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors

Article

作者: Curry, Richard C ; Demko, Suzanne ; DeWire Schottmiller, Mariko Dawn ; Her, Leah ; Cruze, Charles A ; Casey, Denise ; Setty, Bhuvana ; Abdelbaki, Mohamed S ; Cripe, Timothy P

Background:

BXQ-350 is a novel anti-neoplastic agent composed of saposin C (SapC) and phospholipid dioleoylphosphatidyl-serine sodium (DOPS) that selectively binds tumor cell phosphatidylserine (PS), inducing apoptosis. BXQ-350 has demonstrated preclinical antitumor effects in high-grade gliomas (HGG) and clinical activity in adult patients with recurrent HGG.

Methods:

A phase 1 study was conducted in pediatric patients with relapsed/refractory solid tumors, including recurrent brain tumors. Primary objectives were to characterize safety and determine maximum tolerated dose (MTD) and preliminary antitumor activity. Sequential dose cohorts were assessed up to 3.2 mg/kg using an accelerated titration design. Each cycle was 28 days; dosing occurred on days 1-5, 8, 10, 12, 15, and 22 of cycle 1, and day 1 of subsequent cycles, until disease progression or toxicity.

Results:

Nine patients, median age 10 years (range: 4-23), were enrolled. Seven patients (78%) had central nervous system (CNS) and two (22%) had non-CNS tumors. Eight patients completed cycle 1. No dose limiting toxicity (DLT) or BXQ-350-related serious adverse events (SAEs) were observed. Six patients experienced at least one adverse event (AE) considered possibly BXQ-350-related, most were grade ≤2. One patient with diffuse intrinsic pontine glioma experienced stable disease for 5 cycles. The study was terminated after part 1 to focus development on the frontline setting.

Conclusion:

No DLTs or BXQ-350-related SAEs were reported, and the maximal planned dose of 3.2 mg/kg IV was tolerable. Limited safety and efficacy data support continued BXQ-350 development in pediatric HGG; however, early discontinuations for progression suggest novel therapies be assessed at earlier disease stages.

2020-08-01·Molecular therapy : the journal of the American Society of Gene Therapy1区 · 医学

One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer

1区 · 医学

Article

作者: Lumeau, Audrey ; Cordelier, Pierre

Pancreatic cancer progresses silently for decades, commonly resulting in late diagnoses, and limited therapeutic options exist for advanced tumors where surgery is no longer possible.Therapies targeting the stroma as well as immunotherapies hold promise for the future, and recent clinicals trials have revived our hopes for successful targeted therapies in highly selected patients.To date, in the metastatic setting, FOLFIRINOX and gemcitabine ± nab-paclitaxel are standard treatment for patients with good performance status.In this issue of mol. therapy, N'Guessan et al., describe a new combination strategy based on gemcitabine and lipophilic nanovesicles composed of dioleoyl phosphatidylserine(DOPS) for delivery of saponin C (SapCDOPS).SapC-DOPS targets extracellular phosphatidylserine (PS) and activates lysosomal enzymes, provoking apoptotic cell death via ceramide productionThey further show that such a combination results in enhanced cancer cell cytotoxicity in relevant preclin. models.

项与 BXQ-350 相关的新闻（医药）

2026-01-07

·PRNewswire

Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026

COVINGTON, Ky., Jan. 6, 2026 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that the Company will participate in the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 taking place January 8-10, 2026, in San Francisco, California. Details of the posters are included below. First Poster Details: Abstract Title: BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma. Abstract Number: 242 Poster Board Number: K2 Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date: Saturday, January 10, 2026 Session Time: 7:00-7:55 AM Presenter: Dr. Reema Patel Second Poster Details: Abstract Title: A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma. Abstract Number: TPS273 Poster Board Number: L7 Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date: Saturday, January 10, 2026 Session Time: 7:00-7:55 AM Presenter: Dr. Tariq Arshad Third Poster Details: Abstract Title: Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma. Abstract Number: 105 Poster Board Number: D17 Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date: Saturday, January 10, 2026 Session Time: 7:00-7:55 AM Presenter: Michael Gazda, Ph.D. The abstracts are scheduled to be posted to the ASCO GI Online Program at 5 PM ET on Monday, January 6. About BXQ-350 Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents. About Bexion Pharmaceuticals Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion has generated data in multiple classes of solid tumors, including colorectal cancer, high-grade gliomas, and pediatric brain tumors. The Company has completed enrollment in the open label portion of its Phase 1b/2 study evaluating BXQ-350 in combination with the standard of care. The Company has also completed enrollment in a proof-of-concept trial for the treatment of CIPN. Investor and Media Contact: Joyce LaViscount Bexion Pharmaceuticals 859-446-7386 [email protected] SOURCE Bexion Pharmaceuticals, Inc. 21% more press release views with Request a Demo

临床1期ASCO会议

2025-11-09

·允英

【案例报道】32年抗争，晚期脑膜瘤患者经免疫治疗终获‘无瘤’新生

打开公众号，设置“星标”，关注我们了解更多肿瘤资讯！~ 脑膜瘤是常见的中枢神经系统原发肿瘤，其中高级别脑膜瘤（2级和3级）虽然只占总病例的少数，却具有较高的复发风险和有限的治疗选择。脑膜瘤传统的治疗方案是手术和放疗，随着精准医疗的发展，研究人员开始探索脑膜瘤的分子特征，试图找到新的治疗靶点。在这个过程中，一个在肾癌中研究较多的基因，PBRM1，意外地在部分脑膜瘤患者中展现出对免疫治疗的临床潜力。今天分享的案例，是一位脑膜瘤切除后复发的患者，传统治疗和临床试验均失败后，基因检测发现了与免疫疗效相关的PBRM1突变，患者开始尝试免疫治疗，持续获益近4年后肿瘤完全消失，恢复了正常工作和生活。案例介绍一名女性患者，在19岁时（1993年）被诊断出右侧乳突区2级非典型脑膜瘤，先后接受了两次手术和放疗后，度过了十多年的稳定期。直到43岁时（2017年），患者因头痛就诊，影像学检查显示右侧上颈部强化肿块，伴C1-C2骨质侵蚀并延伸至后颅窝。于是患者接受了第一次复发后手术切除（R1），病理证实为非典型脑膜瘤，未见免疫细胞浸润。术后患者使用生长抑素类似物注射治疗，维持了22个月，直至影像学显示疾病进展，患者再次接受大范围手术（R2），病理结果与R1标本相似（图1）。图1.手术后的MRI影像.(A)和(B)R1术后、(C)和(D)R2术后，箭头标记为颅底肿块从传统治疗到精准免疫的转折手术恢复后，患者参加了一项BXQ-350的I期临床试验（NCT02859857）。不幸的是，疾病再次进展，右颅底肿瘤生长，症状加重。为寻找可能的靶向治疗方案，医疗团队对R2标本（右小脑肿瘤）进行了二代测序（NGS）。结果显示：肿瘤突变负荷（TMB）：4 Muts/Mb；微卫星状态：MSS； PD-L1肿瘤比例评分：TPS<1%；基因改变：FBXW7 G419突变、BAP1缺失、PBRM1缺失。基于PBRM1突变在肾细胞癌中与免疫治疗反应相关的证据，医疗团队决定尝试标准剂量的帕博利珠单抗（200mg，每3周一次）治疗。令人振奋的是，仅3个周期后症状就有所改善，患者还恢复了全职工作，且未出现显著不良反应，影像学复查显示肿瘤尺寸缩小，占位近乎消失（图2）。截至文献撰写时，患者已完成66个周期的帕博利珠单抗治疗，持续控制肿瘤近4年，最近的影像学检查发现肿瘤竟完全消失了。她的抗癌之路长达32年，最终获益于免疫治疗，能够持续正常生活与工作且体能状态良好！图2.患者头部MRI影像.(A)和(B)帕博利珠单抗治疗3周期后肿瘤缩小；(C)和(D)免疫治疗66周期后肿瘤消失讨论： PBRM1突变与免疫治疗反应的潜在关联在透明细胞肾细胞癌患者中，PBRM1功能丧失突变常见，且与免疫检查点抑制剂的临床获益相关。Braun等人的研究显示，在接受纳武利尤单抗治疗的189例转移性透明细胞肾细胞癌患者中，55例有PBRM1突变，该突变与临床获益和较长无进展生存期相关。脑膜瘤中PBRM1突变的特点：PBRM1突变在脑膜瘤中不常见（约2.8%），且通常与高级别脑膜瘤相关，预后较差。最近一项850例脑膜瘤患者的病例系列显示，仅16例（1.9%）存在PBRM1失活突变，其中多数（11例）具有乳头状组织学特征且为高级别。所有病例均为微卫星稳定（MSS），中位TMB较低（2.1 Muts/Mb），5例存在BAP1重叠突变。本病例的脑膜瘤检测显示微卫星稳定和PD-L1 TPS＜1%，TMB为4 Muts/Mb，这些免疫相关生物标志物的水平不太可能解释对免疫治疗的阳性反应，提示与肿瘤免疫治疗密切相关的基因PBRM1缺失可能在该患者免疫治疗中发挥了重要作用。读案例提示 1 精准医疗的时代，每一个基因突变都可能成为突破口。即使像PBRM1这样在特定肿瘤中罕见的突变，也可能提供重要的治疗线索，值得在常规基因检测中关注。 2 即使PD-L1表达阴性、TMB不高，检测到与免疫疗效相关的基因仍可能预测免疫治疗获益，拓展免疫治疗的潜在适用人群。参考文献： Reusch E, Peh KH, Morgan R, Momo H, Orren D, Rock S, Pittman T, Neltner J, Kolesar J and Villano J (2025) Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy. Front. Oncol. 15:1587752. 注：本文内容不构成最终临床建议，请以临床医生诊疗建议为准。温馨提示由于微信修改了推送规则，没有点“在看”，会慢慢收不到我们的推送哦。请将“允英”加为星标，每次阅读完后别忘记点下“赞”和“在看”哦。关于允英医疗 YUNYING 允英医疗以长三角区域为中心，辐射全中国，公司致力于打造癌症精准诊疗的新型生态圈，综合运用基因突变检测、基因甲基化检测、基因编辑重组等生物科技的前沿技术，全方位提供从癌症早期精准筛查、癌症靶向用药检测、癌症治疗药物研发一体化的肿瘤精准医学解决方案。允英医疗成立至今，顺利通过近百项由国家卫健委临检中心、国家病理质控中心、美国病理学会等机构组织的室间质评。检验能力获得了美国病理学会(College of American Pathologists，CAP)认证，肿瘤核心基因检测试剂盒通过欧盟CE认证、获得国家药品监督管理局（NMPA）注册批准，且生产管理质量体系获国际ISO13485认证。目前允英已累计为超三十万例肿瘤患者提供精准检测服务，为国内肿瘤精准医疗领域开拓者。同时允英秉承“严谨、高效”的理念，坚守分子诊断技术创新与应用探索，为肿瘤精准医疗与伴随诊断领域的茁壮发展贡献力量。

免疫疗法临床结果

2025-05-28

·PRNewswire

Bexion Pharmaceuticals, Inc. Announces Acceptance of Abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

COVINGTON, Ky., May 28, 2025 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that two abstracts were accepted at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30, 2025 - June 3, 2025, in Chicago, Illinois. Details of the abstracts are included below. Abstract Details: Title: Effect of BXQ-350, a novel sphingolipid metabolism modulator, on neuronal environments through modulation of gene pathways Abstract Number: e24058 Author: Michael Gazda, Tariq Arshad, Jim Beach, Nikhil Wilkins, Adam Creighbaum, Timothy Stephens Session Title: Publication Only: Symptom Science and Palliative Care Title: A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma Abstract Number: e14044 Author: Tariq Arshad, Michael Gazda, Jim Beach, Kathleen Dorris, Margot Lazow, Trent Hummel, Richard Curry III, Adam Creighbaum Session Title: Publication Only: Central Nervous System Tumors The full abstracts are currently available in the ASCO digital program. About BXQ-350 Bexion's lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents. About Bexion Pharmaceuticals Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion has generated data in multiple classes of solid tumors, including colorectal cancer, high-grade gliomas, and pediatric brain tumors. The Company has completed enrollment in the open label portion of its Phase 1b/2 study evaluating BXQ-350 in combination with the standard of care. The Company has also completed enrollment in a proof-of-concept trial for the treatment of CIPN. Investor Contact: William Windham Solebury Strategic Communications 646-378-2946 [email protected] Media Contact: Joyce LaViscount Bexion Pharmaceuticals 859-446-7386 [email protected] SOURCE Bexion Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期ASCO会议

100 项与 BXQ-350 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性结直肠癌	临床2期	美国	Bexion Pharmaceuticals, Inc.	2023-01-09
周围神经系统疾病	临床2期	美国	Bexion Pharmaceuticals, Inc.	2023-01-09
组蛋白H3中K27M点突变的弥漫性中线胶质瘤	临床1期	美国	Bexion Pharmaceuticals, Inc.	2021-05-24
肿瘤过程	临床1期	美国	Bexion Pharmaceuticals, Inc.	2020-06-08
脑癌	临床1期	美国	Bexion Pharmaceuticals, Inc.	2019-04-15
弥漫内生性脑桥神经胶质瘤	临床1期	美国	Bexion Pharmaceuticals, Inc.	2019-04-15
复发性实体肿瘤	临床1期	美国	Bexion Pharmaceuticals, Inc.	2019-04-15
晚期恶性实体瘤	临床1期	美国	Bexion Pharmaceuticals, Inc.	2016-09-01
室管膜瘤	临床1期	美国	Bexion Pharmaceuticals, Inc.	2016-09-01
多形性胶质母细胞瘤	临床1期	美国	Bexion Pharmaceuticals, Inc.	2016-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05322590 (ASCO_GI2026)	临床1/2期	转移性结直肠癌一线	33	BXQ-350 + mFOLFOX7 + Bevacizumab (metastatic colorectal carcinoma)	顧醖淵製夢顧繭糧構膚(鹹齋窪壓淵選糧繭餘襯) = Analysis of Neurofibrillary Light Chain (NfL) biomarkers suggests concordance with physician and patient reported outcomes. 簾糧簾簾鑰積顧製願糧 (蓋獵觸糧鏇顧蓋構糧積 )	积极	2026-01-08
NCT05322590 (ASCO_GI2026)	临床1/2期	转移性结直肠癌一线	34	BXQ-350+mFOLFOX7+Bevacizumab	獵簾壓遞壓鹽鑰範鹽糧(積鏇觸網糧遞網艱夢範) = 窪觸鬱齋鑰鏇繭遞窪鏇淵齋觸構壓獵壓積艱餘 (夢製積顧範齋餘願窪餘 )	积极	2026-01-08
NCT05322590 (P-73 BXQ-350, ESMO_GI2023)	临床1/2期	转移性结直肠癌	-	BXQ-350	衊觸鏇夢網憲廠蓋蓋選(鹽範鑰醖襯襯鹹廠壓遞) = 4 out of 10 patients with chronic CIPN at time of enrollment experienced an improvement of their symptoms 鏇鏇範衊繭壓鬱憲簾網 (構願壓艱鏇構製糧襯簾 )	积极	2023-07-01
NCT02859857 (ASCO_GI2023) 人工标引	临床1期	晚期恶性实体瘤 \| 周围神经系统疾病	73	BXQ-350	網鹽餘壓膚鏇壓鏇顧鹽(範顧網構積鹹鑰願鹽鬱) = 廠鏇襯廠鏇鹽廠鑰鏇繭齋廠膚衊憲積壓願築鹽 (獵鏇顧繭簾製淵顧遞簾 ) 更多	积极	2023-01-24
NCT02859857 (ASCO_GI2023) 人工标引	临床1期	晚期结直肠腺癌	73	BXQ-350	簾衊襯蓋壓淵淵蓋蓋築(網製壓積醖鏇鹽鹽襯鬱) = 簾顧膚繭選窪鬱構鹽窪鬱餘衊簾遞願鹹獵積鏇 (網醖簾顧遞蓋繭構構鏇 ) 更多	积极	2023-01-24
NCT02859857 (ASCO_GI2023) 人工标引	临床1期	晚期结直肠腺癌	73	BXQ-350 (patients with PFS > 6 months)	襯艱積繭壓觸糧廠鏇獵(範積壓壓築網選醖夢積) = 獵衊餘餘夢艱構築夢膚壓襯憲範築願衊觸鹹膚 (選壓顧遞鹽築艱觸衊衊 )	积极	2023-01-24
NCT02859857 (028559857, ASCO2022)	临床1期	晚期恶性实体瘤	-	BXQ-350	積顧觸淵鏇廠簾鹽壓觸(衊網獵繭餘憲製壓淵觸) = 鏇蓋蓋鹽遞餘壓獵構鹹艱壓壓觸築淵繭艱顧築 (壓築廠網範鏇顧壓醖壓 ) 更多	-	2022-06-02
NCT02859857 (RARE-10, SNO2018)	临床1期	室管膜瘤	1	BXQ-350 2.4 mg/kg IV infusion	餘範淵衊餘網鑰製觸網(鏇鏇觸鏇餘顧鹽繭餘鏇) = stable disease per RANO and ECOG of 1 顧選製齋艱廠鑰簾積壓 (蓋壓夢構餘鬱鹽艱壓觸 ) 更多	积极	2018-11-05
NCT02859857 (BXQ-350, SNO2018)	临床1期	高级别胶质瘤 externalized phosphatidylserine	17	BXQ-350 0.7 mg/kg	鹹鏇築構網鹹膚齋網網(構廠膚醖選壓製憲襯憲) = ECOG scores declining from a baseline 0-1 in 2/9 (22%) to 3 窪壓積範夢鏇鑰網蓋願 (遞選鏇遞艱窪網鏇鑰選 ) 更多	积极	2018-11-05
NCT02859857 (BXQ-350, SNO2018)	临床1期	高级别胶质瘤 externalized phosphatidylserine	17	BXQ-350 1.1 mg/kg		积极	2018-11-05